Although bullous pemphigoid (BP), atopic dermatitis (AD), and allergic rhinitis (AR) are associated with shared pathogenic mechanisms the epidemiological relationship between these conditions remains to be investigated.
Objective
To evaluate the bidirectional association of BP with AD and AR.
Methods
A population-based retrospective cohort study was performed comparing BP patients (n = 3924) with age-, sex-, and ethnicity-matched control subjects (n = 19,280), with respect to incident cases of AD and AR. A case-control design was additionally adopted to assess the odds of BP in individuals with a preexisting diagnosis of AD and AR.
Results
The odds of BP was increased after a preexisting diagnosis of AD (fully adjusted odds ratio, 1.76; 95% confidence interval [CI], 1.44–2.15; P < 0.001) and AR (fully adjusted odds ratio, 1.13; 95% CI, 1.01–1.28; P = 0.047). Patients with BP were at an increased risk of subsequent AD (fully adjusted hazard ratio, 2.00; 95% CI, 1.60–2.51; P < 0.001) but not AR (fully adjusted hazard ratio, 1.00; 95% CI, 0.83–1.20; P = 0.997). Compared with other patients with BP, those with BP and comorbid AD and AR were more frequently managed by adjuvant drugs and long-term systemic and topical corticosteroids and had decreased all-cause mortality.
Conclusions
A history of AD and AR confers susceptibility to the development of BP. Awareness of this association may be of help for physicians managing patients with these diseases.
KridinK, ShihadeW, BergmanR. Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis. Acta Derm Venereol, 2019; 99(1):72–77. doi:.
3.
KridinK, SchwartzN, CohenAD, et al.Mortality in bullous pemphigoid: a systematic review and meta-analysis of standardized mortality ratios. J Dermatol, 2018; 45(9):1094–1100. doi:.
4.
JeonHW, YunSJ, LeeSC, et al.Mortality and comorbidity profiles of patients with bullous pemphigoid in Korea. Ann Dermatol, 2018; 30(1):13–19. doi:.
AmberKT, ValdebranM, KridinK, et al.The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease. Front Med (Lausanne), 2018; 5:201. doi:.
7.
MaurerM, AltrichterS, SchmetzerO, et al.Immunoglobulin E–mediated autoimmunity. Front Immunol, 2018; 9:689. doi:.
8.
Van BeekN, LüttmannN, HuebnerF, et al.Correlation of serum levels of ige autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol, 2017; 153(1):30–38. doi:.
9.
LinL, HwangBJ, CultonDA, et al.Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid. J Invest Dermatol, 2018; 138(5):1032–1043. doi:.
10.
VerschoorD, Von GuntenS. Allergy and atopic diseases: an update on experimental evidence. Int Arch Allergy Immunol, 2019; 180(4):235–243. doi:.
11.
StemesederT, KlinglmayrE, MoserS, et al.Influence of intrinsic and lifestyle factors on the development of IgE sensitization. Int Arch Allergy Immunol, 2017; 173(2):99–104. doi:.
12.
StefanovicN, FlohrC, IrvineAD. The exposome in atopic dermatitis. Allergy, 2020; 75(1):63–74. doi:.
BousquetPJ, LeynaertB, NeukirchF, et al.Geographical distribution of atopic rhinitis in the European Community Respiratory Health Survey I. Allergy, 2008; 63(10):1301–1309. doi:.
16.
KridinK, LudwigRJ, SchonmannY, et al.The bidirectional association between bullous pemphigoid and psoriasis: a population-based cohort study. Front Med 2020;7. doi:.
17.
CohenAD, DreiherJ, Regev-RosenbergS, et al.The quality indigators program in Clalit Health Services: the first decade. Harefuah, 2010; 149(4):204–9, 265.
18.
CharlsonME, PompeiP, AlesKL, et al.A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis, 1987; 40(5):373–383. doi:.
19.
LambertsA, MeijerJM, JonkmanMF. Nonbullous pemphigoid: a systematic review. J Am Acad Dermatol, 2018; 78(5):989–995.e2. doi:.
20.
RabinRL, LevinsonAI. The nexus between atopic disease and autoimmunity: a review of the epidemiological and mechanistic literature. Clin Exp Immunol, 2008; 153(1):19–30. doi:.
21.
KeroJ, GisslerM, HemminkiE, et al.Could TH1 and TH2 diseases coexist? Evaluation of asthma incidence in children with coeliac disease, type 1 diabetes, or rheumatoid arthritis: a register study. J Allergy Clin Immunol, 2001; 108(5):781–783. doi:.
22.
SimpsonCR, AndersonWJ, HelmsPJ, et al.Coincidence of immune-mediated diseases driven by TH1 and TH2 subsets suggests a common aetiology. A population-based study using computerized general practice data. Clin Exp Allergy, 2002; 32(1):37–42. doi:.
23.
HsiaoYP, TsaiJD, MuoCH, et al.Atopic diseases and systemic lupus erythematosus: an epidemiological study of the risks and correlations. Int J Environ Res Public Health, 2014; 11(8):8112–8122. doi:.
24.
HouYC, HuHY, LiuIL, et al.The risk of autoimmune connective tissue diseases in patients with atopy: a nationwide population-based cohort study. Allergy Asthma Proc, 2017; 38(5):383–389. doi:.
25.
AndersenYM, EgebergA, GislasonGH, et al.Autoimmune diseases in adults with atopic dermatitis. J Am Acad Dermatol, 2017; 76(2):274–280.e1. doi:.
26.
KrishnaMT, SubramanianA, AdderleyNJ, et al.Allergic diseases and long-term risk of autoimmune disorders: longitudinal cohort study and cluster analysis. Eur Respir J, 2019; 54(5):1900476. doi:.
27.
RenZ, HsuDY, BrievaJ, et al. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A. Br J Dermatol 2017;176(1):87–99. doi:.
28.
KridinK, LudwigRJ, Tzur BitanD, et al.A history of asthma increases the risk of bullous pemphigoid: insights from a large population-based study. Dermatology, 2021; 26:1–8. doi:.
29.
QianY, LinL, MoranTP, et al.Food allergens could promote the TH2 mediated autoantibody development in an autoimmune skin disease bullous pemphigoid. J Immunol, 2020; 204(1Supplement): Available at: https://www.jimmunol.org/content/204/1_Supplement/218.16. Accessed February17, 2021.
30.
TanBK, LiQZ, SuhL, et al.Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol, 2011; 128(6):1198–1206.e1. doi:.
31.
JeffeJS, SeshadriS, HamillKJ, et al.A role for anti-BP180 autoantibodies in chronic rhinosinusitis. Laryngoscope, 2013; 123(9):2104–2111. doi:.
32.
HolmesJ, FaircloughLC, ToddI. Atopic dermatitis and autoimmunity: the occurrence of autoantibodies and their association with disease severity. Arch Dermatol Res, 2019; 311(3):141–162. doi:.
33.
de GraauwE, SitaruC, HornM, et al.Evidence for a role of eosinophils in blister formation in bullous pemphigoid. Allergy, 2017; 72(7):1105–1113. doi:.
34.
Van BeekN, SchulzeFS, ZillikensD, et al.IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases. Expert Rev Clin Immunol, 2016; 12(3):267–277. doi:.
35.
LambPM, PattonT, DengJS. The predominance of IgG4 in prodromal bullous pemphigoid. Int J Dermatol, 2008; 47(2):150–153. doi:.
36.
AsbrinkE, HovmarkA. Serum IgE levels in patients with bullous pemphigoid and its correlation to the activity of the disease and anti–basement membrane zone antibodies. Acta Derm Venereol, 1984; 64(3):243–246.
37.
DelaporteE, Dubost-BramaA, GhohestaniR, et al.IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid. J Immunol, 1996; 157(8):3642–3647. PMID: 8871665.
38.
De BenedettoA, KuboA, BeckLA. Skin barrier disruption: a requirement for allergen sensitization. J Invest Dermatol, 2012; 132(3 pt 2):949–963. doi:.
39.
KuboA, NagaoK, AmagaiM. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J Clin Invest, 2012; 122(2):440–447. doi:.
40.
CiprandiG, VizzaccaroA, CirilloI, et al.Nasal eosinophils display the best correlation with symptoms, pulmonary function and inflammation in allergic rhinitis. Int Arch Allergy Immunol, 2005; 136(3):266–272. doi:.
41.
Ahlstrom-EmanuelssonCA, GreiffL, AnderssonM, et al.Eosinophil degranulation status in allergic rhinitis: observations before and during seasonal allergen exposure. Eur Respir J, 2004; 24(5):750–757. doi:.
42.
KämpeM, StoltI, LampinenM, et al. Patients with allergic rhinitis and allergic asthma share the same pattern of eosinophil and neutrophil degranulation after allergen challenge. Clin Mol Allergy 2011;9. doi:.
43.
KridinK, CohenAD. Dipeptidyl-peptidase IV inhibitor–associated bullous pemphigoid: a systematic review and meta-analysis. J Am Acad Dermatol, 2021; 85:501–503. doi:.
44.
KatohN, HiranoS, SuehiroM, et al.Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26. Clin Exp Immunol, 2000; 121(2):187–192. doi:.
45.
PatelPM, JonesVA, KridinK, et al.The role of dipeptidyl peptidase-4 in cutaneous disease. Exp Dermatol, 2021; 30(3):304–318. doi:.
46.
TasicT, BäumerW, SchmiedlA, et al.Dipeptidyl peptidase IV (DPP4) deficiency increases TH1-driven allergic contact dermatitis. Clin Exp Allergy, 2011; 41(8):1098–1107. doi:.
47.
GlinskiW, Stepien-SopniewskaB, Korczak-KowalskaG, et al.Modulation of CD3-dependent lymphocyte proliferation by extracellular matrix proteins in atopic dermatitis. Acta Derm Venereol, 1995; 75(5):353–356. doi:.
48.
KridinK, Zelber-SagiS, KhamaisiM, et al.Remarkable differences in the epidemiology of pemphigus among two ethnic populations in the same geographic region. J Am Acad Dermatol, 2016; 75(5):925–930. doi:.
